Citadel Advisors
PMCB icon

Citadel Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Citadel Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$239K Buy
359,547
+129,825
+57% +$99.3K ﹤0.01% 11015
2025
Q4 		$166K Buy
229,722
+215,191
+1,481% +$194K ﹤0.01% 11205
2025
Q3 		$14.1K Buy
+14,531
New +$14.5K ﹤0.01% 12539
2024
Q2 		– Sell
-8,561
Closed -$20.3K – 15122
2024
Q1 		$20.3K Sell
8,561
-20,057
-70% -$43.4K ﹤0.01% 13009
2023
Q4 		$61.8K Sell
28,618
-6,766
-19% -$14.7K ﹤0.01% 11561
2023
Q3 		$74.3K Sell
35,384
-29,524
-45% -$75.3K ﹤0.01% 11257
2023
Q2 		$186K Sell
64,908
-11,103
-15% -$33.3K ﹤0.01% 10006
2023
Q1 		$221K Buy
76,011
+58,508
+334% +$172K ﹤0.01% 10005
2022
Q4 		$51.1K Buy
+17,503
New +$50.1K ﹤0.01% 12109
2022
Q3 		– Sell
-31,696
Closed -$80.2K – 13361
2022
Q2 		$72K Buy
+31,696
New +$69.3K ﹤0.01% 11687

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Citadel Advisors's PMCB Position: Q1 2026 in Review

Citadel Advisors increased its PharmaCyte Biotech (PMCB) stake by 57% in Q1 2026, buying an estimated $99.3K and bringing the position to 359,547 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #11015.

Citadel Advisors first reported a position in PMCB in Q2 2022 and has held it in 10 quarters since. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Citadel Advisors held 359,547 shares of PharmaCyte Biotech worth $239K as of Q1 2026.
  • Citadel Advisors bought 129,825 PharmaCyte Biotech shares in Q1 2026, an estimated $99.3K.
  • PharmaCyte Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11015 holding.
  • Citadel Advisors first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 10 quarters since.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.